Merus and Halozyme partner on subcutaneous petosemtamab formulation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/17/2026
- Wall Street tumbles as worries about AI trade and high oil prices weigh
- Oil touches $110 a barrel for first time since May on Middle East, Russia supply fears
- Stay risk-off as higher real yields and AI volatility threaten stocks: BofA
- Apple’s first foldable iPhone sells out within minutes as preorders begin
- CoreWeave bond rout tests market's math on AI buildout
| Halozyme Therapeutics, Inc. (NASDAQ: HALO) | Delayed: 121.84 +0.33 (0.27%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $121.51 | 52 Week High | $18.39 | |||
| Open | $122.19 | 52 Week Low | $6.96 | |||
| Day High | $122.45 | P/E | N/A | |||
| Day Low | $120.19 | EPS | $-0.58 | |||
| Volume | 2,082,593 | |||||
| (NASDAQ: MRUS) | Delayed: 90.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $90.00 | 52 Week High | $19.63 | |||
| Open | $90.00 | 52 Week Low | $7.26 | |||
| Day High | $90.00 | P/E | N/A | |||
| Day Low | $90.00 | EPS | $0.00 | |||
| Volume | 720,454 | |||||
